Recce Pharmaceuticals Ltd
RECEF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 9.6% | 56.9% | 41.5% | – |
| Gross Profit | -$0 | -$0 | $0 | $0 |
| % Margin | -39.1% | -5.4% | 95% | 93.9% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -270.8% | -311.7% | -389.2% | -350% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -285.4% | -257.8% | -299.6% | -356.1% |
| EPS Diluted | -0.09 | -0.1 | -0.074 | -0.063 |
| % Growth | 9.3% | -34% | -19% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |